The whole world is fighting with the COVID-19 pandemic, which traps people home, causing high business and economic losses, and above all, leads to very serious deaths. The lack of a valid, accepted treatment protocol and vaccine that leads to continued treatment searches. Leng et al published their article in the Aging and Disease journal, which demonstrates that mesenchymal stem cells (MSCs) can be used for COVID-19 treatment. Adipose tissue is one of the most important MSCs sources in the body, and adipose derived stromal cells (ADSCs) from adipose tissue are also one of the most valuable components of stromal vascular fraction (SVF). Finally, Gentile and Sterodimas, have also published their article for the potential use of SVF in COVID-19 treatment in Aging and Disease journal. Their publication has been a guide in many ways. Adipose tissue-derived stromal cells have three main features: Immunomodulatory, anti-inflammatory and regenerative. Immunomodulator effects are used as a preventive in patients prone to disease; its anti-inflammatory effects may allow them to be used as a therapeutic during active disease period and finally regenerative effects to repair post-disease sequale. Those cells can be obtained not only enzymatically, but also mechanically with very benefits. They can be delivered not only systemically through the IV route but also to the target organ with a carrier. While suggesting any adipose tissue-derived treatment method possibility, the relation of adipose tissue COVID-19 should not be ignored. Because, COVID-19 shows its effect through ACE-2 and adipose tissue is very rich and important tissue in terms of ACE-2.
Morestin H (1915). Quelques cas de greffes graisseuse appliquees aIa chirurgie reparatrice. Bull Mem Soc Chir (Paris), 41:1631
Jarrell BE, Williams SK, Stokes G, et al. (1986). Use of freshly isolated capillary endothelial cells for the immediate establishment of a monolayer on a vascular graft at surgery. Surgery, 100(2): 392-399.
Zuk PA, Zhu M, Mizuno H, et al. (2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue engineering, 7(2): 211-228.
Leng Z, Zhu R, Hou W, et al (2020). Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis, 11:216-228.
Shetty AK (2020). Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia. Aging Dis, 11(2): 462-464.
Ozturk S, Elcin AE, EWlcin YM (2020). Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes? Aging Dis, in press
Chen J, Hu C, Chen L, et al (2020). Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment. Engineering, in press.
Gentile P, Sterodimas A (2020). Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-DiseaseAging Dis, 11(2)
Schildberg FA, Donneberg VS (2018). Stromal cells in health and disease. Cytometry, 93(9):871-875
Bourin P, Bunnell BA, Casteilla L, et al. (2013). Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy, 15(6): 641-648.
Ullah M, Liu DD, Thakor AS (2019). Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement. iScience, 15: 421-438.
Bari E, Ferrarotti I, Saracino L, et al. (2020). Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use. Cells, 9(4), E924.
Zimmerlin L, Donnenberg VS, Rubin, et al. (2013). Mesenchymal markers on human adipose stem/progenitor cells. Cytometry. Part A, 83(1): 134-140.
Al-Ghadban S, Bunnell BA (2020). Adipose Tissue-Derived Stem Cells: Immunomodulatory Effects and Therapeutic Potential. Physiology, 35(2):125-133.
Fukui E, Funaki S, Kimura K, et al. (2019). Adipose Tissue-Derived Stem Cells Have the Ability to Differentiate into Alveolar Epithelial Cells and Ameliorate Lung Injury Caused by Elastase-Induced Emphysema in Mice. Stem cells international, 2019: 5179172.
Silva JD, Lopes-Pacheco M, Paz A, et al. (2018). Mesenchymal Stem Cells From Bone Marrow, Adipose Tissue, and Lung Tissue Differentially Mitigate Lung and Distal Organ Damage in Experimental Acute Respiratory Distress Syndrome. Critical care medicine, 46(2): e132-e140.
Sun Z, Li F, Zhou X, et al. (2018). Stem cell therapies for chronic obstructive pulmonary disease: current status of pre-clinical studies and clinical trials. Journal of thoracic disease, 10(2): 1084-1098.
Sesé B, Sanmartín, J M, Ortega B, et al. (2019). Nanofat Cell Aggregates: A Nearly Constitutive Stromal Cell Inoculum for Regenerative Site-Specific Therapies. Plastic and reconstructive surgery, 144(5): 1079-1088.
Ghiasloo M, Lobato RC, Díaz JM, et al. (2020). Expanding Clinical Indications of Mechanically Isolated Stromal Vascular Fraction: A Systematic Review. Aesthetic surgery journal, in press
Ryan PM, Caplice NM (2020). Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation and Cytokine Amplification in COVID-19. Obesity, in press.
Li MO, Flavell RA (2008). Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity,28(4): 468-476.
Khoury M, Cuenca J, Cruz FF, et al. (2020). Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19. European respiratory journal, in press.
Lopes-Pacheco M, Robba C, Rocco P, et al. (2020). Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome. Cell biology and toxicology, 36(1):83-102.
Garg RK, Rennert RC, Duscher D, et al. (2014). Capillary force seeding of hydrogels for adipose-derived stem cell delivery in wounds. Stem cells translational medicine, 3(9):1079-1089.
Bari E, Ferrarotti I, Saracino L, et al. (2020). Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use. Cells, 9(4): E924.
Hoogduijn MJ, Lombardo E (2019). Mesenchymal Stromal Cells Anno 2019: Dawn of the Therapeutic Era? Concise Review. Stem cells translational medicine, 8(11):1126-1134.
Ji F, Li L, Li Z, et al. (2020). Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019. Stem cells translational medicine, in press.
Zimmerlin L, Rubin JP, Pfeifer ME, et al (2013). Human adipose stromal vascular cell delivery in a fibrin spray. Cytotherapy, 15(1):102-108.
Hoffmann M, Schroeder S, Kleine-Weber H, et al. (2020). Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19. Antimicrobial agents and chemotherapy, in press.
Shetty R, Ghosh A, Honavar S, et al. (2020). Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future. Indian journal of ophthalmology, 68(5):693-702.
Engeli S, Gorzelniak K, Kreutz R, et al. (1999). Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 17: 555-560
Karlsson C, Lindell K, Ottosson M, et al. (1998). Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab, 83: 3925-3929
Pahlavani M, Kalupahana NS, Ramalingam, et al (2017). Regulation and Functions of the Renin-Angiotensin System in White and Brown Adipose Tissue. Comprehensive Physiology, 7(4):1137-1150.
Slamkova M, Zorad S, Krskova K (2016). Alternative renin-angiotensin system pathways in adipose tissue and their role in the pathogenesis of obesity. Endocrine regulations, 50(4):229-240.
Jia X, Yin C, Lu S, et al. (2020). Two Things About COVID-19 Might Need Attention Preprints, in press.
Slamkova M, Zorad S, Krskova K (2016). Alternative renin-angiotensin system pathways in adipose tissue and their role in the pathogenesis of obesity. Endocr Regul, 50(4):229-240.